AI Healthcare Companies in 2026 — A Curated Vendor Map (Clinical AI, Diagnostics, Drug Discovery, Mental Health)

The buyer question we hear most from CIOs and chief medical officers in 2026 is not "does AI work in healthcare," it is "which AI healthcare companies are actually production-ready, and which are pilot theatre." The vendor count keeps growing. The FDA AI/ML device list crossed 950 in early 2026. Disclosed venture funding into AI healthcare companies from 2024 through Q1 2026 is past $31B. Sorting signal from noise is now the hard part of buying. Related: our model selection guide for healthcare AI.

We build custom AI for healthcare clients (RAG over clinical guidelines, ambient documentation, claims triage agents) and we evaluate third-party vendors as part of our discovery audit. That gives us a working view of which AI healthcare companies hold up under real procurement scrutiny: HIPAA + SOC 2 Type II evidence, named hospital systems in production, FDA pathway, eval methodology that does not collapse on independent data, and EHR integration depth in Epic, Oracle Health (Cerner), athenahealth, or Meditech. Related: how we run LLM evaluations in our delivery practice. The build work behind those healthcare systems is our AI development practice.

This map is different from the Forbes or MedicalFuturist lists in three ways. It is current to mid-2026. It is categorized by use case, not by company size. And it splits production-ready categories from pilot-only ones, because we have watched too many health systems sign multi-year agreements for technology that is not yet ready to leave the research department. Every company below is named because they are publicly known to be working in this space. Treat specific hospital deployments as the best-known public reference at time of writing and re-verify before any procurement decision.

How we evaluate ai healthcare companies

Before naming any companies, the criteria. Our delivery team uses the same scoring rubric whether we are advising on a build-versus-buy decision or shortlisting vendors for a 4-6 week pilot. Six things matter, in this order. The full rubric — six axes including recovery-after-error and refusal calibration — is in our AI agent reliability evaluation methodology.

# Score an ai healthcare company against a buyer brief.
weights = {
    "fda_clearance": 0.25,
    "named_health_systems_live": 0.25,
    "published_eval": 0.15,
    "ehr_integration_depth": 0.20,
    "hipaa_soc2_evidence": 0.10,
    "pricing_transparency": 0.05,
}

def score(vendor):
    return sum(
        weights[k] * vendor.signals.get(k, 0)
        for k in weights
    )

# We score every vendor on a 0-1 scale per signal.
# Vendors that beat 0.65 go to a paid pilot; below that we pass.

Clinical AI + ambient documentation companies

Ambient documentation is the category with the cleanest ROI math in AI healthcare right now. The clinician puts a phone or laptop on the desk, the model listens to the visit, and an Epic note appears in the inbasket. The technology is good enough to draft, the human signs. Pilot studies across multiple AMCs report 5-7 hours of documentation time saved per clinician per week. These are the AI healthcare companies that buyers are actually paying production money to. Our own production reference in this category is our HIPAA-scoped clinical triage RAG agent, running on Claude Sonnet 4.6 + FHIR R4 over 14,200 shadow encounters with a 38–62% wait-time reduction.

Abridge

Carnegie Mellon spinout, founded 2018. Generative AI that produces structured SOAP notes from ambient conversation, with bidirectional ICD-10 and CPT coding suggestions. Publicly disclosed deployments include Kaiser Permanente, Mayo Clinic, UPMC, Emory, and Christus Health. Their May 2024 and 2025 funding rounds put them above a $2.5B valuation. We have seen Abridge produce the cleanest first-draft notes in head-to-head pilots, particularly for primary care and cardiology specialty languages. Production-readiness: high.

Suki AI

Suki Assistant is a voice-activated scribe with deep Epic, Oracle Health Cerner, athena, and Meditech integration. Publicly named customers include CommonSpirit Health, Texas Health Resources, and MedStar. The pitch we hear in pilots: Suki ships across all four major EHRs out of the box, which matters for multi-EHR systems post-acquisition. Production-readiness: high. The differentiator versus Abridge is breadth of EHR coverage rather than note quality.

Microsoft DAX Copilot (formerly Nuance)

Nuance is now Microsoft. DAX Copilot is the GPT-powered successor to DAX Express, embedded inside the Microsoft cloud and inside Epic's Hyperdrive workspace. Publicly disclosed customers include Atrium Health, Stanford Health Care, and dozens of large IDNs that already run on Microsoft 365 and Azure. The buyer story is straightforward: if procurement already has Microsoft enterprise agreements, DAX Copilot is the path of least resistance. Production-readiness: high. The trade-off versus startups is feature velocity; you get Microsoft stability rather than weekly model improvements.

Augmedix

Augmedix was acquired by Commure in late 2024, and the combined platform is now sold under Commure branding with Augmedix Go and Augmedix Live as products. Strong in emergency department and inpatient settings where the visit cadence breaks consumer-style scribes. Production-readiness: high in ED, medium in ambulatory after the Commure consolidation.

Hippocratic AI

Polaris is Hippocratic safety-focused LLM aimed at non-diagnostic patient-facing tasks: pre-op education, chronic-disease check-ins, discharge follow-ups. Their stated approach is constellation of agents with a clinical safety supervisor model. Disclosed pilots include Cedars-Sinai, WellSpan, and several payer-side care management programs. Production-readiness: medium. We have heard mixed clinician feedback about agent rigidity; the safety scaffolding sometimes prevents the conversation from getting to a useful answer. The category is real; the bar to call it production-grade for clinical use is still rising.

Notable

Notable is positioned across patient intake, scheduling, prior authorization, and revenue cycle. Less a scribe than a workflow-automation layer for administrative tasks. Disclosed customers include Intermountain Health, North Kansas City Hospital, and several independent multispecialty groups. Production-readiness: high in administrative workflows, lower as you move toward clinical decision-impacting tasks.

Top ai medical imaging companies and ai radiology companies

Imaging is the most mature AI category in healthcare. The FDA AI/ML device list is dominated by radiology clearances. The buying question has shifted from "can AI read a scan" to "which AI radiology companies integrate with our PACS and read worklist without breaking radiologist throughput." These are the ai medical imaging companies we see in active production at academic and community sites.

Aidoc

Aidoc holds the largest installed base for ED triage AI in the United States, with deployments at Cedars-Sinai, Yale New Haven, and many community ED groups. Their FDA-cleared products cover intracranial hemorrhage, pulmonary embolism, cervical-spine fracture, and abdominal free gas. Published prospective sensitivity for PE triage sits around 94% across multi-site studies. Production-readiness: high. The buyer trade-off is workflow rather than accuracy; Aidoc is best when the ED is the volume center.

Rad AI

Rad AI is the productivity-side bet: Omni Impressions auto-generates the impressions block of a radiology report, Continuity closes the follow-up loop on incidental findings. Customers include UCSF, University of Maryland, and large outpatient imaging groups. Production-readiness: high for reporting workflow. The reported throughput uplift sits around 20% for radiologists who fully adopt it.

Annalise.ai

Australian-founded, with FDA clearances on multi-finding chest X-ray (over 120 findings on the latest model) and head CT. Strong outside the US, growing in US community radiology. Production-readiness: high for CXR, medium for CT in US deployments.

Gleamer

Paris-headquartered, with BoneView for musculoskeletal trauma X-ray and ChestView for lung. Heavy European installed base, expanding in the US. Production-readiness: high for MSK trauma detection in ED and urgent care.

Tempus AI

Tempus is the cross-category player: clinical and molecular data platform, oncology imaging, ECG analysis (Tempus ECG-AF cleared), real-world evidence. They IPO'd in 2024 (NASDAQ: TEM). The buyer story for hospitals is data partnership as much as software. Production-readiness: high in oncology and cardiology data products. We treat Tempus as a platform partner rather than a single-point vendor.

PathAI

Digital pathology, biomarker discovery for pharma, and AISight as the lab IT layer. PathAI has academic medical center pilots and pharma partnerships with Bristol Myers Squibb and others. Production-readiness: medium in clinical pathology (most US labs are still digitizing slides), high in pharma research workflows.

AI drug discovery companies

Drug discovery is the AI healthcare category with the most capital and the longest payback. No AI-designed small molecule has yet received FDA approval. Several are in Phase 1 and Phase 2 trials, and the next 18-36 months will be the first real read on whether the ai drug discovery companies below produce clinically and commercially meaningful assets.

Insilico Medicine

Integrated platform (Pharma.AI) covering target identification, generative chemistry, and clinical-trial design. Their lead asset Rentosertib (formerly INS018_055) for idiopathic pulmonary fibrosis is in Phase 2a, and is the most advanced AI-discovered + AI-designed small molecule we know of. Multiple pharma partnerships disclosed (Sanofi, Exelixis). Production-readiness in the discovery sense: high. Drug approval: years away.

Recursion Pharmaceuticals

Phenomics-driven platform (cellular imaging at industrial scale) merged with Exscientia in 2024, broadening from biology to chemistry. Multi-year deals with Roche/Genentech and Bayer. Public on NASDAQ (RXRX). Several Phase 2 assets in oncology and rare disease. The most diversified pipeline among the ai drug discovery companies.

Atomwise

Structure-based ligand discovery using convolutional models. Long-standing partnership history with Eli Lilly and Bayer, plus a wide AIMS academic collaboration program. Smaller wholly-owned pipeline than Recursion or Insilico; the business is more partnership-oriented.

Insitro

Founded by Daphne Koller. Machine learning over human genetics and induced-pluripotent stem cell data. Major collaboration with Bristol Myers Squibb in neurodegeneration and oncology, and earlier work with Gilead in NASH. Pre-clinical and Phase 1 assets disclosed. The most biology-data-heavy player in this category.

Isomorphic Labs

Alphabet spinout sitting on top of AlphaFold and successors. Pharma deals with Novartis and Eli Lilly disclosed in 2024. No own-pipeline clinical assets yet (as of public information at time of writing); the bet is structural-biology depth that the rest of the field cannot match.

AI mental health companies

Mental health is where the regulatory story is moving fastest. FTC enforcement actions and several state attorneys general have warned against autonomous therapy chatbots. The ai mental health companies still standing tend to do one of three things: route to human clinicians, focus on screening rather than therapy, or hold FDA breakthrough designation that gives them a regulatory anchor.

Spring Health

Employer-mediated mental health benefit. AI is used for precision matching of members to therapists and for symptom tracking, not for autonomous therapy. Large employer customer base. Production-readiness: high in the employer benefits channel.

Lyra Health

Closest competitor to Spring Health in the employer benefits market. Hybrid model with provider network and AI-supported member experience. Strong Fortune 500 customer list publicly disclosed.

Woebot Health

Rules-based CBT chatbot with FDA Breakthrough Device designation for postpartum depression and adolescent depression. The strategic question for Woebot has been whether to step into generative AI or stay rules-based for safety. Recent restructuring has tightened the focus. Production-readiness: medium, pending the next regulatory milestone.

Wysa

UK-headquartered, FDA Breakthrough Device designation, NHS partnerships, B2B sales into employer and payer channels. Public published outcomes in peer-reviewed journals. One of the better evidence bases in the category.

AI clinical decision support companies

Clinical decision support is the category with the highest ceiling and the most awkward present. The ai clinical decision support companies below are real, but most are still in pilot or limited production. The biggest deployed system in the category is also the most-criticized.

Epic (Sepsis Model + new generative tools)

The Epic Sepsis Model is the most deployed clinical AI predictor in the United States by raw site count, and also the most studied. The JAMA Internal Medicine 2021 external validation reported lower real-world performance than vendor-quoted figures. Epic has since revised the model and added generative-AI tools inside Hyperdrive. The lesson for buyers is that being native in the EHR does not exempt a model from independent validation.

Glass Health

Differential diagnosis and clinical plan generation aimed at clinicians at the point of care. The product is positioned cautiously as decision support, not autonomous diagnosis. Adoption is strongest with residents and academic medicine teaching environments. Production-readiness: medium, growing.

OpenEvidence

Free clinician-facing search and synthesis tool over the medical literature. Backed by NEJM Group, with strong physician word-of-mouth in 2024-2025. Not a clinical-decision system in the regulated sense; closer to a faster way to read the literature. Production-readiness: high for that use case.

Hippocratic AI (CDS-adjacent)

Already named under clinical AI above. Mentioned again because Polaris occupies a gray zone between patient education and decision support. We expect more regulatory scrutiny here as agents start to handle more medication-related conversations.

AI healthcare startups worth watching (early-stage)

The ai healthcare startups list rotates fast. The companies below are venture-backed by tier-1 funds (a16z, Sequoia, GV, Founders Fund, General Catalyst), and our delivery team sees them most often in client procurement and partnership discussions in 2026. This is a snapshot, not a permanent ranking; the early-stage cohort changes quarterly.

Sword Health

Virtual musculoskeletal care with computer-vision movement tracking and AI-supported clinical workflows. Strong employer-channel growth, late-stage funding rounds in 2024-2025. Reported outcomes published with peer-reviewed studies.

K Health

Symptom triage and primary-care chat product, with partnership deployments through Cedars-Sinai and Mayo Clinic Hera-K joint venture history. Has pivoted product positioning multiple times; the underlying triage corpus is one of the largest in the category.

Counterpart Health

Spun out of Clover Health to commercialize Clover Assistant, the chronic-condition decision-support tool used by Clover MA primary care network. Risk-adjusted population health is the bet. The product has real production miles inside Clover and is now opening to external payers.

Memora Health

Patient navigation and care-program automation via SMS plus LLM. Acquired by Commure in 2024 as part of the General Catalyst-backed roll-up. Now sold inside the Commure suite alongside Augmedix Live.

Eleos Health

Behavioral health-specific ambient documentation plus measurement-based care. Different category from Abridge and Suki because behavioral health visits have different documentation requirements and CPT codes. Strong vertical focus.

Iambic Therapeutics

Newer ai drug discovery startup with its own clinical assets (oncology focus) advancing in early clinical trials. Worth watching as the next-cohort competitor to Insilico and Recursion.

AI medical companies for revenue cycle and operations

Revenue cycle is where most ai medical companies actually make money today. The clinical-AI press cycle gets the headlines, but billing, coding, prior authorization and denials management are the categories where AI is paying for itself inside hospitals and physician groups right now.

Notable

Already named under clinical AI. Strongest production deployments are in patient intake, scheduling, prior authorization, and registration accuracy rather than clinical documentation.

Iodine Software

AwareCDI for clinical documentation integrity and AwareUM for utilization management. Large hospital installed base. Production-readiness: high in the CDI category. Most CFOs we talk to know Iodine by name.

Waystar AltitudeAI

Waystar is the publicly traded revenue cycle platform (NASDAQ: WAY). AltitudeAI is their AI overlay across claim editing, denial prediction, and prior authorization. The bet is that AI features are easier to monetize from inside an installed RCM platform than as a separate product.

Cohere Health

Prior authorization automation on the payer side, primarily Medicare Advantage. Humana is the disclosed flagship customer. Production-readiness: high inside contracted payers.

Production-ready versus pilot-only: a category map

We sort AI healthcare companies into three readiness buckets when advising clients. Production-ready means buyers should be signing multi-year contracts and integrating into core workflows. Pilot-ready means a 4-6 week limited deployment makes sense, but full procurement is premature. Watch-list means real innovation, no buyer action yet.

When to build custom versus buy from an ai healthcare company

Not every AI workload in healthcare is a buy. The general rule we use with clients: buy the FDA-regulated diagnostic tools (you cannot get to market faster than a company that already has clearance), build the workflow and data-glue layers (those are where your competitive moat sits), and run a deliberate hybrid where you take vendor APIs and wrap them in your own orchestration, identity, audit and eval layers.

Our delivery practice runs a 1-2 week discovery audit before any AI healthcare build. The audit covers vendor shortlisting (using the rubric earlier in this article), a build-versus-buy recommendation per use case, an eval methodology proposal, a security and compliance gap check (HIPAA, SOC 2, HITRUST), and a 4-6 week pilot scope with weekly eval gates. After pilot, continuous engagements run with a dedicated team for monitoring, eval refresh, and feature work.

Two patterns we see repeatedly in healthcare engagements: clients overestimate how much off-the-shelf vendors will customize to their workflow (most will not, the unit economics do not support it), and clients underestimate how much eval, observability, and HITL design they need around any vendor model that touches a clinician. Both gaps are where a delivery partner pays for itself.

If you are scoping a healthcare AI build, our /industries/healthcare/ page covers the operator playbook for HIPAA-grade deployments. For custom model and RAG work, see /services/ai-development/ and /services/ai-knowledge-base/.

FAQs

What are the top ai healthcare companies in 2026?

By production deployment volume in US hospitals, the top ai healthcare companies cluster around three categories: ambient documentation (Abridge, Suki, Microsoft DAX Copilot), radiology triage (Aidoc, Rad AI, Annalise.ai), and revenue cycle (Notable, Iodine, Waystar). On valuation and capital raised, the leaders are Tempus AI (publicly listed), Abridge, Hippocratic AI, Recursion, and Insilico Medicine. Any "top" list is workload-dependent; ask for the category before the ranking.

Which ai healthcare companies are FDA-cleared?

The FDA AI/ML device list crossed 950 entries in early 2026 and is dominated by radiology. Aidoc, Rad AI, Annalise.ai, Gleamer, and Tempus all hold multiple clearances. Outside imaging, Woebot Health and Wysa hold FDA Breakthrough Device designations in behavioral health. Most ambient documentation companies (Abridge, Suki, DAX) are not FDA-regulated because the clinician signs every note and retains final responsibility.

Are ai healthcare companies profitable?

Most are not yet GAAP-profitable. The clearest path to profitability today runs through revenue cycle and ambient documentation, where per-encounter or per-clinician pricing scales cleanly. AI drug discovery companies will not be profitable for years; their model is option value on the asset pipeline. The publicly listed players (Tempus, Recursion, Waystar) disclose financials and are worth reading directly rather than relying on press coverage.

What is the difference between ai healthcare companies and ai healthcare startups?

We treat ai healthcare companies as the broader set including public companies (Tempus, Waystar, Recursion), late-stage privates (Abridge, Hippocratic, Sword Health), and acquired or merged players (Nuance inside Microsoft, Augmedix inside Commure). AI healthcare startups specifically refers to early- and growth-stage privately held companies, usually Series A through C. The two lists overlap heavily, but the startup label implies a different risk profile for buyers and investors.

How do you evaluate an ai healthcare vendor?

Six criteria, in this order: regulatory clearance, security and compliance posture (HIPAA, SOC 2 Type II), named production deployments with disclosed go-live dates, prospective eval and bias audit, EHR integration depth, and disclosed commercial terms. We covered the full rubric earlier in the article. The two-question filter we run first: ask for a prospective validation study and a SOC 2 Type II dated within the last 12 months.

Which ai healthcare companies should buyers shortlist in 2026?

For ambient documentation: Abridge, Suki, DAX Copilot. For radiology: Aidoc, Rad AI, Annalise.ai. For RCM and prior auth: Notable, Iodine, Waystar AltitudeAI, Cohere Health. For employer behavioral health benefits: Spring Health, Lyra. For oncology data platforms: Tempus AI. That is the buyer shortlist most of our healthcare clients converge on in 2026 procurement cycles. Treat it as a starting point and run our six-criterion rubric against any vendor before signing.

The AI healthcare companies that win the next 24 months will be the ones with the cleanest evidence, the deepest EHR integration, and the most honest readiness messaging. Our delivery team is happy to map any of the above against a specific procurement question as part of a discovery audit. If you are deciding between two named vendors, or between buy-versus-build for a clinical workflow, that is where we add the most value.